Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation

Subjects

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  Google Scholar 

  2. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.

    Article  CAS  Google Scholar 

  3. Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N et al. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia 2014; 29: 51–57.

    Article  Google Scholar 

  4. Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577–584.

    Article  Google Scholar 

  5. Piñana JL, Martino R, Barba P, Margall N, Roig MC, Valcárcel D et al. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience. Bone Marrow Transplant 2010; 45: 534–542.

    Article  Google Scholar 

  6. Martino R, Piñana JL, Parody R, Valcarcel D, Sureda A, Brunet S et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant 2009; 44: 749–756.

    Article  CAS  Google Scholar 

  7. Sorror ML . How I assess comorbidities before hematopoietic cell transplantation. Blood 2013; 121: 2854–2863.

    Article  CAS  Google Scholar 

  8. Iacobelli S . Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013; 48: S1–37.

    Article  Google Scholar 

  9. Kaplan EL, Meier P . Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  10. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA . Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3: 143–152.

    Article  Google Scholar 

  11. Barba P, Martino R, Pérez-Simón JA, Fernández-Avilés F, Castillo N, Piñana JL et al. Combination of the hematopoietic cell transplantation comorbidity index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014; 20: 66–72.

    Article  Google Scholar 

  12. ElSawy M, Storer BE, Sorror ML . To combine or not to combine: optimizing risk assessment before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014; 20: 1455–1456.

    Article  Google Scholar 

  13. Barba P, Piñana JL, Martino R, Valcárcel D, Amorós A, Sureda A et al. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant 2010; 16: 413–420.

    Article  Google Scholar 

  14. Xhaard A, Porcher R, Chien JW, de Latour RP, Robin M, Ribaud P et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia 2008; 22: 2062–2069.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was funded by Instituto de Salud Carlos III, Spain (PI1100872, RD06/0020/0101, RD12/0036/0071, EC07/90065), Pla Recerca de Catalunya (2009-SGR-168), Marató TV3 (100830/31/32) and Fundacion Cellex, Spain, to JS.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P Barba.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barba, P., Martino, R., Orti, G. et al. Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 50, 1371–1374 (2015). https://doi.org/10.1038/bmt.2015.144

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.144

This article is cited by

Search

Quick links